Sunday, October 26, 2025

Calochortus persistens: Yoga genetics' conversation - How to develop a #YogaGeneticsConversation & @WorldUnivAndSch re e.g. "#YogaGenetics? For performance - higher faster stronger athletics - & #ETHICS?" here ~ http://www.scottmacleod.com/yoganotations.html ~ & more supple too: https://scott-macleod.blogspot.com/2025/10/red-hibiscus.html & https://scott-macleod.blogspot.com/search/label/Yoga & https://wiki.worlduniversityandschool.org/wiki/Yoga? * * Can any genetic drug therapies today - that are FDA-approved - affect physical processes such as running, jumping or athletic movement for athletes or for for example help Down syndrome people or autistic people? And further can any genetic drug therapies help such people at this point with physical movement questions?



TwitterX - How to develop a #YogaGeneticsConversation & @WorldUnivAndSch ?

How to develop a #YogaGeneticsConversation & @WorldUnivAndSch re e.g. "#YogaGenetics? For performance - higher faster stronger athletics - & #ETHICS?" here ~ http://www.scottmacleod.com/yoganotations.html ~ & more supple too: https://scott-macleod.blogspot.com/2025/10/red-hibiscus.html & https://scott-macleod.blogspot.com/search/label/Yoga & https://wiki.worlduniversityandschool.org/wiki/Yoga?

https://x.com/Q_YogaMacFlower/status/1982497077944078591

https://x.com/scottmacleod/status/1982497918067298813

https://x.com/sgkmacleod/status/1982497225113792871

https://x.com/WUaSPress/status/1982497273344065762

https://x.com/HarbinBook/status/1982497361873235976

https://x.com/TheOpenBand/status/1982497508891984334

https://x.com/WorldUnivAndSch/status/1982497755034689715



--





San Francisco Bay Area - East Bay Hills & Online

415 480 4577

World University and School's wiki, 'Yoga,' subject page - https://wiki.worlduniversityandschool.org/wiki/Yoga :) - with an invitation to 'edit this page' to learn or teach and explore yoga. 


Yoga ideas
#QuakerYogaMacFlower 
#DesiderataWUaS
~#ToolifyAIWUaS #WUaSBliss 
~#YogaNotationsWUaS
~#YogaWUaS @
#FriendlyQuakerWUaS ðŸ¥°
#WUaSabolition in #RealisticVirtualEarth #WUaSYoga ~

with pic of partner child pose - supported backbend 




* 




How could a '#YogaGenetics? For performance - higher faster stronger athletics - & #ETHICS?' - http://www.scottmacleod.com/yoganotations.html - more supple too  yoga genetics conversation from vaccines and from genetic drug therapies influence Yoga asana & for example the study of Yoga bliss Samadhi ... and Dhyana and Dharana too?


Discussions surrounding genetic technologies, including vaccines and drug therapies, could significantly impact the understanding and practice of yoga, particularly advanced states like Dharana, Dhyana, and Samadhi. The concept of "YogaGenetics" raises questions about how the pursuit of athletic enhancement ("higher faster stronger") intersects with yoga ethics and the definition of human potential. For more information, visit ScottMacLeod


AND

The "bliss" in the eight limbs of yoga is found in Samadhi, the eighth and final limb, which means enlightenment, union, or pure bliss. The journey to this state is described as a path of increasing focus and internal awareness, with words like Dhyana (meditation) and Dharana (concentration) leading up to this ultimate absorption. 
The eight limbs of yoga
  1. Yama: Ethical standards and social discipline.
  2. Niyama: Personal observances and self-discipline.
  3. Asana: Physical postures.
  4. Pranayama: Breath control.
  5. Pratyahara: Withdrawal of the senses.
  6. Dharana: Focused concentration.
  7. Dhyana: Meditation and absorption.
  8. Samadhi: Bliss or enlightenmen


 





* 
Yoga genetics conversation

A "yoga genetics conversation" refers to 
scientific research and discussion on how yoga influences gene expression and epigenetics, impacting health markers like inflammation and cellular longevity. Studies show that regular yoga practice can lead to molecular changes, such as downregulating pro-inflammatory genes and upregulating anti-inflammatory ones, by influencing epigenetic modifications like DNA methylation and histone modification. This has led to the understanding that mind-body practices leave a "molecular signature" that can improve health and well-being. 
Molecular mechanisms and impacts of yoga on gene expression 
  • Anti-inflammatory effects: Yoga can decrease the expression of pro-inflammatory genes like 
    image.gif
     and 
    image.gif
     while boosting anti-inflammatory genes, which may reduce the risk of inflammation-related diseases.
  • Stress reduction: By influencing the stress response, yoga can reverse stress-related changes in genes and even activate genes related to stress resilience.
  • Cellular health and longevity: Yoga is associated with activating the enzyme telomerase, which is linked to cellular longevity and maintaining telomere length. It may also promote DNA repair mechanisms and protect cellular integrity.
  • Brain health: Yoga can enhance gene expression related to brain health, including neuroprotective genes and microRNA-29c, which is involved in the antiviral response. 
How it works: Epigenetics 
  • Gene expression vs. genetic code: Genetics are the blueprint, while gene expression is how those genes are used to create proteins. Yoga doesn't change the underlying DNA sequence but can change which genes are turned on or off.
  • Epigenetic modifications: These changes happen through processes like DNA methylation and histone modifications, which are influenced by lifestyle factors, including practices like yoga.
  • Molecular signature: Yoga leaves a "molecular signature" in cells that alters gene expression in ways that promote health and well-being. 
Research and limitations 
  • Growing evidence: A growing body of evidence supports the link between yoga and positive changes in gene expression and epigenetic modifications.
  • Need for more research: While promising, the field is still developing. Further research with larger sample sizes and longer-term studies is needed to fully understand the mechanisms and therapeutic potential




* 

yoga genetics conversation on how vaccines and genetic drug therapies might influence Yoga asana & other aspects of 8 limb yoga


Emerging research in genetics and epigenetics—the study of how lifestyle and environment affect gene expression—offers a nuanced perspective on the interplay between modern medicine and ancient practices like yoga. While there is no evidence that vaccines directly alter DNA, genetic drug therapies are designed to do so, which raises compelling questions about how these interventions might interact with the profound mind-body changes sought through the 8-limbed path of yoga. 
The genetic backdrop of yoga: Epigenetic influence
Recent studies have validated yoga's impact at the molecular level, particularly on the field of epigenetics, which is the modification of gene expression without altering the underlying DNA sequence. 
  • Stress reduction: Yoga practice has been shown to downregulate genes related to the inflammatory response (like NF-κB and IL-6) and stress pathways (HPA axis).
  • Immune function: Researchers have observed that yoga can rapidly produce changes in gene expression that boost the immune system.
  • Cellular repair: Practices that include asana, pranayama, and meditation may activate genes involved in DNA repair and longevity, like p53 and telomerase. 
This means yoga is not just a physical or mental practice; it is a lifestyle intervention that can fundamentally alter cellular function and promote overall well-being by communicating with our genetic code. 
How vaccines might influence yoga practice
Vaccines are a form of preventive medicine that introduces weakened or killed pathogens, or parts of them, to trigger an immune response. The interaction with yoga is not one of direct genetic alteration, but rather in the context of their impact on the body and immune system. 
  • Immune response and energy: A vaccine prompts a temporary, heightened immune response. This can cause temporary fatigue or lethargy, which could influence a practitioner's energy levels and capacity for intense physical asana or deep meditation in the short term.
  • Bodily awareness: A temporary sensation of being unwell post-vaccine could be incorporated into one's yoga practice by emphasizing sensitivity and self-awareness. It may encourage a gentler, more restorative practice rather than a vigorous one, strengthening the aspect of pratyahara (withdrawal of the senses) as one listens to the body's needs.
  • Immune support: Given that yoga has been shown to improve immune function at the genetic level, a consistent practice could potentially support the body's response to a vaccine, though this is speculative and not a substitute for medical advice. 
How genetic drug therapies might influence yoga
Unlike vaccines, genetic drug therapies, such as those that use messenger RNA (mRNA) or gene editing tools, are designed to influence the body's genetic machinery directly. This introduces a new level of complexity when considering their interaction with an integrative practice like yoga. 
  • Complementary mechanisms: A genetic therapy could be designed to target a specific problematic gene expression, such as one causing an inflammatory condition. A complementary yoga practice might reinforce the therapy's effects by further downregulating the same pro-inflammatory gene pathways, creating a powerful synergistic effect.
  • Altered internal landscape: Some genetic therapies may alter cellular metabolism or stress responses. As practitioners of the 8-limbed path (including pranayama, or breath control, and dhyana, meditation) become more attuned to subtle internal sensations, they might experience different physiological responses than before the therapy. A heightened awareness (pratyahara) would be necessary to notice these internal shifts.
  • Tailored practice: A patient undergoing genetic therapy may need a modified yoga practice. For example, a therapy targeting a musculoskeletal disorder might initially cause discomfort, requiring less strenuous asanas. A yoga therapist could create a tailored program to work in concert with the drug regimen, emphasizing aspects like breathwork and meditation to manage pain and anxiety.
  • Ethical implications: A conversation on genetics and yoga would need to address the ethical considerations of altering one's genetic blueprint. A yogic practitioner, grounded in tenets like ahimsa (non-harming) and saucha (purity), might question the philosophical implications of such interventions and how they affect the body's natural state. 
A dialogue on the 8 limbs
  1. Yamas and Niyamas (ethics and observances): The ethical dimensions of genetic therapies would be a major topic. How do we balance technological advancement with the natural evolution of our bodies? What are our responsibilities to future generations (aparigraha—non-hoarding)?
  2. Asana (physical postures): Genetic factors influence a person's natural flexibility, joint structure, and muscle composition. As genetic therapies evolve, they could influence an individual's physical limitations and abilities. How might a practitioner’s asana evolve if a therapeutic intervention alters their physiology? The focus would need to remain on internal awareness and self-acceptance rather than on external comparison.
  3. Pranayama (breath control): The effects of genetic therapies on the nervous system could alter breathing patterns and energetic flow. Practitioners would need to pay close attention to how their prana (life force) is affected, using their breathwork to consciously find balance and stability.
  4. Pratyahara (withdrawal of the senses): A practitioner would need to cultivate a deep level of internal listening to observe any physiological changes induced by a genetic therapy. This could be a powerful way to understand the body's response to the treatment, rather than just relying on external medical reports.
  5. Dharana, Dhyana, and Samadhi (concentration, meditation, and enlightenment): The ultimate spiritual limbs of yoga are concerned with mental focus and unity. Some studies show meditation affects genes related to neuroplasticity and brain health. It's possible that genetic therapies targeting the nervous system could alter a meditator's experience, either by enhancing their capacity for focus or by introducing new challenges. The core practice of meditation would remain a tool for navigating these shifts and seeking deeper truths beyond the physical form


--




San Francisco Bay Area - East Bay Hills & Online

415 480 4577

World University and School's wiki, 'Yoga,' subject page - https://wiki.worlduniversityandschool.org/wiki/Yoga :) - with an invitation to 'edit this page' to learn or teach and explore yoga. 


Yoga ideas
#QuakerYogaMacFlower
#DesiderataWUaS
~#ToolifyAIWUaS #WUaSBliss 
~#YogaNotationsWUaS
~#YogaWUaS @
#FriendlyQuakerWUaS ðŸ¥°
#WUaSabolition in #RealisticVirtualEarth #WUaSYoga ~

with pic of partner child pose - supported backbend 





 


* * 



Can any genetic drug therapies today - that are FDA-approved - affect physical processes such as running, jumping or athletic movement for athletes or for for example help Down syndrome people or autistic people? And further can any genetic drug therapies help such people at this point with physical movement questions?




Yes, some FDA-approved genetic drug therapies can improve physical movement, primarily by treating underlying genetic conditions that cause muscle weakness or impaired physical function.  

For example, a gene therapy is approved for Duchenne muscular dystrophy (DMD) to improve motor function, and a drug is approved for Barth syndrome to improve muscle strength, which can affect abilities like walking, running, and physical activity. Currently, there are no FDA-approved genetic drug therapies specifically for Down syndrome or autism for the purpose of enhancing physical movement, although research in this area is ongoing






*
a gene therapy is approved for Duchenne muscular dystrophy (DMD) to improve motor function




+7
Yes, a gene therapy called ELEVIDYS (delandistrogene moxeparvovec-rokl) has been approved by the FDA for Duchenne muscular dystrophy (DMD) to improve motor function. Initially granted accelerated approval in 2023 for ambulatory patients ages 4–5, the therapy was later granted full approval for ambulatory patients and accelerated approval for non-ambulatory patients. It works by delivering a micro-gene to muscle cells to produce a shortened version of the dystrophin protein, which helps stabilize muscle cells. 
How it works
AAV vector: The therapy uses a harmless adeno-associated virus (AAVrh74) to deliver the therapeutic DNA into muscle cells. 
Micro-dystrophin: The delivered micro-gene produces a shortened version of the dystrophin protein, called micro-dystrophin. 
Muscle stabilization: This micro-dystrophin helps stabilize muscle cell membranes, which can improve motor function and potentially lead to a milder form of the disease. 
Approval and patient population
Approved for: Patients aged 4 and older with a confirmed mutation in the DMD gene. 
Initial accelerated approval (June 2023): For ambulatory patients aged 4–5. 
Full approval (June 2024): For ambulatory patients aged 4 and older. 
Accelerated approval (June 2024): For non-ambulatory patients. 
Important considerations
Antibody testing: Patients must be tested for pre-existing antibodies against the delivery virus (AAVrh74), as antibodies can make a patient ineligible for the therapy. 
Clinical benefit: Clinical trials have shown a statistically significant improvement in dystrophin expression and motor function for young patients treated with the therapy, compared to untreated individuals. 
Cost and access: The high cost of the therapy has sparked debate about its accessibility and long-term impact


*
a gene drug is approved for Barth syndrome to improve muscle strength



*
Sep 19, 2025 — Forzinity's accelerated approval is based on improved strength of the muscle used to straighten the leg at the knee. FDA considers this ...
Sep 19, 2025 — FORZINITY™ is indicated to improve muscle strength in adult and pediatric patients with Barth syndrome weighing at least 30 kg. This indication ...
Page includes:
Sep 24, 2025 — The FDA approves Forzinity (elamipretide HCl) to improve muscle strength in adult and pediatric patients with Barth syndrome weighing at least ...
Sep 22, 2025 — Forzinity (elamipretide) is the first medicine to receive accelerated approval from the FDA for improving muscle strength in people with Barth ...
Forzinity is the first FDA-approved therapy specifically for Barth syndrome. It works by targeting mitochondria and stabilizing a lipid called cardiolipin ...
Page includes:
Sep 19, 2025 — Clinical studies show elamipretide can improve mitochondria function and boost muscle strength by 45% and heart function by 40% in patients with ...
Sep 29, 2025 — Elamipretide, now known by its brand name Forzinity, is the first therapy cleared for Barth syndrome and also the first FDA-approved ...
Sep 19, 2025 — FORZINITY™ is indicated to improve muscle strength in adult and pediatric patients with Barth syndrome weighing at least 30 kg. This indication ...
Sep 23, 2025 — The U.S. FDA has granted accelerated approval to Forzinity (elamipretide HCI) for the treatment of patients with Barth syndrome.
Oct 9, 2025 — FORZINITY™ is a mitochondrial cardiolipin binder indicated to improve muscle strength in adult and pediatric patients with Barth syndrome ...

Ask anything in AI Mode

What types of mitochondria-targeted therapies are in development?
What were the results of the TAZPOWER clinical trial?
What are the eligibility criteria for elamipretide treatment for Barth syndrome?
What are some side effects of elamipretide injections?
People also search for

a gene drug is approved for Barth syndrome to improve muscle strength
+6
The drug Forzinity (elamipretide) is the first therapy approved by the FDA for Barth syndrome to improve muscle strength, for use in adult and pediatric patients weighing at least 30 kg. It works by targeting and improving the function of faulty mitochondria, the "powerhouses" of cells that are affected by Barth syndrome. 
  • How it works: 
    Elamipretide is a peptide that binds to a key lipid in mitochondrial membranes, which helps to improve mitochondrial function, boost energy production, and reduce oxidative stress. 
  • Indication: 
    It is indicated to improve muscle strength in adult and pediatric patients with Barth syndrome who weigh at least 30 kg. 
  • FDA approval: 
    The U.S. Food and Drug Administration (FDA) granted accelerated approval in September 2025 based on data showing improvement in knee extensor muscle strength. 
  • Administration: 
    The drug is administered via daily subcutaneous injection. 
  • Potential side effects: 
    Common side effects include injection site reactions like redness, pain, and swelling, which are typically mild to moderate. 
  • Important note: 
    Continued approval depends on future verification of clinical benefit in confirmatory





*



See motor function data from a mutation-agnostic therapy with an established safety profile. Compare DMD therapy vs placebo. Significant clinical differences reported at 18 months. Duvyzat® Clinical Results.
Oct 23, 2024 — A trial showed statistically significant improvement in the expression of dystrophin and improvement in motor function in 4- and 5-year-olds ...
Page includes:
Jun 22, 2023 — FDA Approves Elevidys, a gene therapy for the treatment of pediatric patients 4 through 5 years of age with Duchenne muscular dystrophy ...
by Y Shimizu-Motohashi · 2025 · Cited by 1 — Delandistrogene moxeparvovec, the first FDA-approved gene therapy for DMD ... DMD do not target dystrophin directly, but aim to enhance muscle function.
Oct 14, 2025 — Three boys with DMD given the gene therapy GNT0004 in a trial showed sustained improvements in motor function after two years.
Feb 27, 2025 — ... improve muscle function and slow progression of the disease. Elevidys is not a cure for DMD, and long-term effectiveness is still being studied.
Dec 26, 2024 — A new gene therapy, ELEVIDYS, has been approved to treat older Duchenne muscular dystrophy (DMD) patients. ... improve motor function, ...
Aug 7, 2025 — This document addresses gene therapy for Duchenne muscular dystrophy (DMD), a rare and serious genetic disease affecting muscle strength and movement.

Ask anything in AI Mode

What mutations in the DMD gene does delandistrogene moxeparvovec target?
What are the risks of delandistrogene moxeparvovec for Duchenne muscular dystrophy?
How does the micro-dystrophin produced by gene therapy affect motor function in DMD patients?
Compare clinical trial results for ambulatory vs. non-ambulatory patients with delandistrogene moxeparvovec
by Y Shimizu-Motohashi · Cited by 1 — Delandistrogene moxeparvovec, the first FDA-approved gene therapy for DMD, has demonstrated transgene expression and potential functional ...
Videos
A groundbreaking gene replacement therapy offers hope to Duchenne muscular dystrophy patients, potentially curing the disease and improving their quality of life.
Cash, a 6-year-old boy with DMD, receives Alvites or Dandistrogene moxarbac, a gene therapy that offers hope for slowing disease progression and improving quality of life.
Gene therapy trial for DMD shows promising results, with participants maintaining mobility and experiencing improved quality of life.
Feedback
This newly approved gene therapy delivers a copy of a gene that encodes a shortened, functional form of dystrophin, the gene that is mutated in DMD patients.
gene therapy is approved for Duchenne muscular dystrophy (DMD) to improve motor function
+7
Yes, a gene therapy called ELEVIDYS (delandistrogene moxeparvovec-rokl) has been approved by the FDA for Duchenne muscular dystrophy (DMD) to improve motor function. Initially granted accelerated approval in 2023 for ambulatory patients ages 4–5, the therapy was later granted full approval for ambulatory patients and accelerated approval for non-ambulatory patients. It works by delivering a micro-gene to muscle cells to produce a shortened version of the dystrophin protein, which helps stabilize muscle cells. 
How it works
  • AAV vector: 
    The therapy uses a harmless adeno-associated virus (AAVrh74) to deliver the therapeutic DNA into muscle cells. 
  • Micro-dystrophin: 
    The delivered micro-gene produces a shortened version of the dystrophin protein, called micro-dystrophin. 
  • Muscle stabilization: 
    This micro-dystrophin helps stabilize muscle cell membranes, which can improve motor function and potentially lead to a milder form of the disease. 







* 










https://www.npsoregon.org/wp/rareplants/




https://en.wikipedia.org/wiki/Calochortus_persistens

https://species.wikimedia.org/wiki/Calochortus_persistens


https://commons.wikimedia.org/wiki/Calochortus_persistens

https://commons.wikimedia.org/wiki/Category:Calochortus_persistens

https://commons.wikimedia.org/wiki/Category:Calochortus_persistens?uselang=war

...



at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.